Zymeworks Inc.

We’re looking forward to participating in the @Stifel Virtual Targeted Oncology Forum this week. Management will take part in a fireside chat on May 20 at 9:00 am ET - join the webcast: event.summitcast.com/view/SScpdhHfw…

We just wrapped a great week at PEGS Boston and appreciated the opportunity to connect with so many colleagues advancing the field of antibody engineering. Our team was proud to share some of our latest work — thank you to everyone who stopped by to connect! If you missed the presentations or want to revisit the data, access the presentations here: zymeworks.com/publications/ Curious about our ADC and multispecific programs? Learn more at zymeworks.com/innovation/ #ADC #antibodydrugconjugate #trispecifics #PEGSBoston

We’re pleased to welcome Paul Schneider as our new General Counsel. With more than 20 years of legal experience advising on strategic transactions across the life sciences sector – including in-licensing, out-licensing, collaborations, and M&A – his combination of legal expertise and scientific background will be valuable as we continue advancing our pipeline and business. We also extend our sincere thanks to our outgoing General Counsel, Daniel Dex, for his contributions over the past several years. Since joining Zymeworks in 2017, he has played an important role in helping shape the company and has been a trusted advisor to leadership. We are grateful for his impact and wish him all the best in his next chapter.

Management are pleased to present at the following investors conferences in May and June - learn more: ir.zymeworks.com/news-releases/…

We’re heading to the 2026 Respiratory Innovation Summit in Orlando, FL (May 15–16), hosted by the American Thoracic Society! Our team will present “ZW1528: IL-4Rα x IL-33 Bispecific Antibody for Treatment of COPD” (poster no. 117), showcasing our work on our novel IL-4Rɑ x IL-33 bispecific molecule targeting respiratory inflammation, including mixed-type chronic obstructive pulmonary disease (COPD). Stop by to connect with our team and learn more about our AIID programs. Learn more: zymeworks.com/zymeworks-to-p… #RespiratoryInnovation #COPD #Bispecific #AIID

Ovarian cancer remains one of the most challenging cancers to diagnose and treat — with many patients facing limited options, especially in later stages. Advancing new approaches is critical to changing this reality. On World Ovarian Cancer Day, we recognize the urgency of continued research and innovation — and the importance of working toward better outcomes for patients. #WorldOvarianCancerDay #OvarianCancer #OncologyResearch #OvarianCancerAwareness

Today we reported our Q1 2026 financial results. Join our management team for a live webcast at 4:30 pm ET as we review business updates and progress across our pipeline. Join the webcast: edge.media-server.com/mmc/p/d5i66787/ Read the press release: ir.zymeworks.com/news-releases/…

We’re heading to PEGS Boston next week! Join us for: Panel Advancing Multispecific Antibodies and Combination Therapies to the Clinic May 13 | 2:40 pm ET Presenter: Dr. Nina E. Weisser Posters Uniting Discovery Strategy and Engineering for the Best-in-Class Antibodies for ADC May 12 | 4:00 pm ET May 13 | 6:20 pm ET Presenter: Dr. Germanna Righetto TriTCE Co-Stim: A Differentiated T Cell Engager Platform with Conditional cis CD28 Co-Stimulation May 14 | 8:50 am ET Presenter: Dr. Genevieve Desjardins If you’re attending, we’d welcome the opportunity to connect. Learn more about our ADC and multispecific programs: zymeworks.com/antibody-scien… #PEGSBoston #ADC #Multispecifics #Biotech

May is National Cancer Research Month. Our mission is rooted in advancing science that makes a meaningful difference for patients with difficult to treat cancers. Through our fully integrated, in-house R&D engine, we’re working to translate innovative science into potential new treatment options. To the researchers, clinicians, and patients driving progress forward — we’re proud to be part of this effort. Learn more: zymeworks.com/innovation/ #CancerResearch #Biotech #Innovation #Oncology

May is Mental Health Awareness Month — a reminder that taking care of our mental well-being is just as important as physical health. At Zymeworks, we’re committed to fostering a workplace where our people feel supported, balanced, and empowered to do their best work — for themselves and for the patients we serve. Our Health & Wellness benefits programs, such as ZymeLife and Flexible Time-off, are designed to support employees in prioritizing their well-being. Learn more: zymeworks.com/careers/ #MentalHealthAwarenessMonth #MentalHealthAtWork

Congratulations to the team at @BeOneMedicines on this important milestone! The FDA’s Priority Review highlights the potential of this combination approach in the first-line treatment of HER2-positive gastroesophageal adenocarcinoma—an area with significant unmet need for patients. #GEA #oncology

We’re pleased to share news from our partner, @JazzPharma! Backed by Phase 3 data, this sBLA highlights an important step forward to redefine care for people living with HER2+ gastroesophageal adenocarcinoma, where significant unmet need remains.

AACR 2026 was amazing! A week full of science, collaboration, and connection — and a great reminder of the collective effort driving progress in cancer research. We couldn't be more proud of our team for their hard work that goes into the science behind our programs and leading up to our presentations. Explore all that Zymeworks shared at AACR: loom.ly/-u8s5X4 #AACR26 #Oncology

Today we celebrate Earth Day and reaffirm our commitment to taking actions to protect our planet and environment. As we work to develop novel medicines for patients with difficult-to-treat cancers and other serious diseases, we recognize the importance of minimizing our environmental footprint and are actively working towards sustainable solutions. Read our 2025 ESG report: loom.ly/OFT3ALg

On National Administrative Professionals Day, we extend our deepest thanks to our administrative team at Zymeworks—your professionalism, care, and behind-the-scenes leadership are essential to advancing our mission. #collaboration #AdministrativeProfessionalsDay

Today we presented new Phase 1 Data for our folate receptor alpha-targeting antibody-drug conjugate at #AACR26. The ADC demonstrates encouraging anti-tumor activity in heavily pretreated ovarian and endometrial cancers, regardless of FRα expression. “We are highly encouraged by the initial clinical data for ZW191, which reinforce the strength of our ADC platform and its ability to generate differentiated therapeutics. The breadth and durability of responses, along with activity across varying levels of FRα expression, support further development of ZW191 as a potential best-in-class agent for patients with ovarian and endometrial cancers.” - Dr. Sabeen Mekan, SVP and Chief Medical Officer. View the presentation: zymeworks.com/wp-content/upl… Read our press release: ir.zymeworks.com/news-releases/…

#AACR26: Samuel Lawn, Principal Scientist, will be presenting "ZW439, a novel CLDN18.2-targeting pan-RAS inhibitor antibody drug conjugate for the treatment of RAS mutated pancreatic cancer" at Poster Board 10 in Poster Section 10 from 2 pm - 5 pm PT. His poster is also available on our website: loom.ly/VVHmhDE

Live at #AACR26 - Associate Director Dunja Urosev
and Scientist Ambroise Wu are presenting "ZW427, a Ly6E-targeting antibody drug conjugate bearing a novel pan-RAS inhibitor payload for the treatment of RAS mutated cancers." Stop by Poster Board 9 in Poster Section 12 between 9:00 am to Noon PT to learn more! The poster is also available online: loom.ly/G4MROMs

#AACR26: Mark Petersen, Senior Scientist, ADC Therapeutic Development presents "Design and evaluation of mRNA translation inhibitors for use as antibody drug conjugate payloads" from 9:00 am to Noon PT at Poster Board 8 in Poster Section 38. Check out his poster here: loom.ly/zqiZ-Qk